Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Price Target at $14.20
by Amy Steele · The Cerbat GemShares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $14.20.
A number of research firms have weighed in on CMPX. Guggenheim reissued a “buy” rating and set a $12.00 target price on shares of Compass Therapeutics in a research report on Tuesday, March 24th. Jefferies Financial Group reissued a “buy” rating and set a $9.00 target price on shares of Compass Therapeutics in a research report on Thursday, March 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. Craig Hallum began coverage on shares of Compass Therapeutics in a research report on Friday, February 13th. They set a “buy” rating and a $15.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, January 21st.
Get Our Latest Analysis on CMPX
Compass Therapeutics Price Performance
Compass Therapeutics stock opened at $5.44 on Friday. The firm has a market cap of $979.69 million, a price-to-earnings ratio of -12.65 and a beta of 1.49. Compass Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.88. The firm has a fifty day moving average price of $5.69 and a two-hundred day moving average price of $5.19.
Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. As a group, sell-side analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Compass Therapeutics during the fourth quarter valued at about $132,000. Seven Fleet Capital Management LP acquired a new position in shares of Compass Therapeutics during the fourth quarter valued at about $3,054,000. Invesco Ltd. raised its position in shares of Compass Therapeutics by 5.3% during the fourth quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after buying an additional 3,245 shares during the last quarter. XTX Topco Ltd raised its position in shares of Compass Therapeutics by 582.2% during the fourth quarter. XTX Topco Ltd now owns 115,634 shares of the company’s stock valued at $621,000 after buying an additional 98,684 shares during the last quarter. Finally, Ikarian Capital LLC acquired a new position in shares of Compass Therapeutics during the fourth quarter valued at about $4,296,000. Institutional investors and hedge funds own 68.43% of the company’s stock.
About Compass Therapeutics
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.